Building a Tool to Predict Liver Cancer Risk in Chronic Hepatitis B
Builds a model to predict liver cancer risk in adults with hepatitis B.
Plain-language title generated from the registry record
Registry title: HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with hepatitis B-related liver fibrosis or cirrhosis who are on antiviral treatment and have follow-up records. It builds a model to predict liver cancer (HCC) risk.
- Age
- 18 years or older
- Sex
- Both sexes can join
- Disease stage
- Liver fibrosis or cirrhosis caused by hepatitis B, found by clinical assessment or liver tissue examination
- Earlier treatment
- Must be on antiviral treatment
Main reasons for not taking part
- Liver cancer (HCC) or liver transplant at baseline or within 6 months after enrolment
- Other chronic liver diseases, such as genetic or metabolic liver disease, drug-induced liver injury, or severe steatotic liver disease
- Other cancers, except those considered to have no sign of disease left
- Follow-up shorter than 0.5 years or longer than 5 years
- Fewer than two follow-up visits or outcomes that cannot be traced
Read by machine on 9 November 2026.
Where in China
- Beijing Friendship Hospital, Capital Medical UniversityBeijing, ChinaContact: Jialing ZhouNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Friendship Hospital
- Trial code
- NCT07780357
- Record updated
- 28 August 2026
- Original description
The investigators propose to construct and validate an early HCC risk prediction model in a multicenter retrospective cohort of hepatitis B-related fibrosis/cirrhosis patients, using multimodal data encompassing longitudinal clinical data, serum glycomics profiles, and liver biopsy histopathological images.Read full original descriptionShow less
Development and Application of an HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
The investigators propose to construct and validate an early HCC risk prediction model in a multicenter retrospective cohort of hepatitis B-related fibrosis/cirrhosis patients, using multimodal data encompassing longitudinal clinical data, serum glycomics profiles, and liver biopsy histopathological images.
Inclusion: Aged ≥18 years, both sexes eligible; Diagnosed with hepatitis B-related liver fibrosis or cirrhosis based on clinical assessment or liver histopathology; Undergoing antiviral treatment; Follow-up duration between 0.5- 5 years; Availability of baseline data and at least two longitudinal follow-up visits; Clinical outcomes during the follow-up period are traceable.
Exclusion: Diagnosis of Hepatocellular carcinoma (HCC) or liver transplantation at baseline or within 6 months after baseline/enrollment; Coexisting other chronic liver diseases, such as genetic/metabolic liver diseases, drug-induced liver injury, or severe steatotic liver disease; Coexisting other malignancies (except those considered cured).